Quantcast

KemPharm, Inc. to Present at Cowen and Company 34th Annual Health Care Conference

February 26, 2014

CORALVILLE, Iowa, Feb. 26, 2014 /PRNewswire/ — KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, announced today that President and CEO, Travis Mickle, Ph.D., will present at the Cowen and Company 34(th) Annual Health Care Conference at the Boston Marriott Copley Place in Boston, MA.

Among the topics to be discussed, Dr. Mickle will provide an overview of KemPharm’s development pipeline, including KP201, the company’s lead clinical candidate for the treatment of acute moderate to moderately severe pain. Composed of hydrocodone chemically bound to a ligand, KP201 offers unique physicochemical and pharmacological attributes that may deliver additional patient benefits, including reduced potential for abuse and reduction or elimination of opioid-induced constipation (OIC).

Details of KemPharm’s presentation are as follows:

    Event:                    Cowen and Company 34th
                              Annual Health Care
                              Conference

    Date:                    Tuesday, March 4, 2014

    Time:                    2:30 pm, EST

    Location:                 MIT Room, 3rd Floor -
                              Boston Marriott Copley
                              Place

About KemPharm

KemPharm is a biopharmaceutical company focused on the discovery and development of new chemical entities (NCEs) to treat serious medical conditions through its proprietary and broadly applicable Ligand Activated Therapy (LAT) approach. The company utilizes its LAT technology to generate improved prodrug versions of FDA approved drugs in the high needs areas of pain, ADHD and other CNS diseases. KemPharm’s lead clinical candidate, KP201, is in development for the treatment of acute, moderate to moderately severe pain. Composed of hydrocodone chemically bound to a ligand, KP201 offers unique physicochemical and pharmacological attributes that may deliver additional patient benefits, including reduced potential for abuse and reduction or elimination of opioid-induced constipation (OIC). KemPharm’s pipeline is also highlighted by KP511, its hydromorphone prodrug for pain, KP606, its oxycodone prodrug for pain, and KP415, a prodrug of methylphenidate for the treatment of ADHD. For more information on KemPharm, please visit the company’s website at www.kempharm.com.

    For KemPharm, Inc: Media / Investor Contacts:

    Christal Mickle    Jason Rando / Joshua Drumm, Ph.D.

    319-665-2575       Tiberend Strategic Advisors, Inc.

    info@kempharm.com  212.827.0020

                       jrando@tiberend.com

                       jdrumm@tiberend.com

SOURCE KemPharm, Inc.


Source: PR Newswire



comments powered by Disqus